In addition, SGLT2 inhibitors have been found to relieve hyperuricemia in diabetic mice (Lu et al. 2020), and obesity in high fat-fed mice via enhancing CREB phosphorylation (Yang et al. 2021). Here, SLC5A2 is linked to obesity disorder.